{"organizations": [], "uuid": "b535904f6413482ca04bbd967d3db22ae3528b00", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-knight-therapeutics-says-will-have/brief-knight-therapeutics-says-will-have-exclusive-rights-to-market-and-sell-tenapanor-in-canada-idUSFWN1R10JK", "country": "US", "domain_rank": 408, "title": "BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T12:36:00.000+02:00", "replies_count": 0, "uuid": "b535904f6413482ca04bbd967d3db22ae3528b00"}, "author": "", "url": "https://www.reuters.com/article/brief-knight-therapeutics-says-will-have/brief-knight-therapeutics-says-will-have-exclusive-rights-to-market-and-sell-tenapanor-in-canada-idUSFWN1R10JK", "ord_in_thread": 0, "title": "BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​", "locations": [], "entities": {"persons": [{"name": "knight", "sentiment": "none"}], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "ardelyx inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "knight therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 37 AM / Updated 10 minutes ago BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​   March 19 (Reuters) - Ardelyx Inc: * KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​ * KNIGHT THERAPEUTICS - ‍WILL PAY UP TO C$25 MILLION IN TOTAL PAYMENTS INCLUDING AN UPFRONT PAYMENT AND DEVELOPMENT AND SALES MILESTONES * KNIGHT THERAPEUTICS INC - ‍KNIGHT WILL HAVE EXCLUSIVE RIGHTS TO MARKET AND SELL TENAPANOR IN CANADA​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-19T12:36:00.000+02:00", "crawled": "2018-03-19T12:55:49.000+02:00", "highlightTitle": ""}